1.Diagnostic Analysis for Meniscal Lesions of the Knees
Seung Ki JEONG ; Woo Cheon LEE ; Chun Gyun NA
The Journal of the Korean Orthopaedic Association 1987;22(1):140-144
We assessed the accuracy of clinical evaluation, arthrography and arthroscopy in the diagnosis of meniscal lesions in ninty knees in which arthrotomy was performed for disabling symptoms after evaluation by these three methods. At surgery, ninty-two menisci were removed, of which seventy-two were abnormal and twenty were normal. In these ninty-two menisci, correct diagnostic rate was made clinically 78%, arthrographically 70% and arthroscopically 86%. Arthrographic diagnosis was least accurate for lesions of the lateral meniscus and arthroscopic diagnosis was least accurate for lesions of the posterior horn of the medial meniscus and peripheral lesions. Based on this study, it was concluded that both the arthrography and arthroscopy are valuable technique for diagnosis of meniscal lesions.
Animals
;
Arthrography
;
Arthroscopy
;
Diagnosis
;
Horns
;
Knee
;
Menisci, Tibial
2.Intraneural Ganglion of the Common Peroneal Nerve: A Case Report
Seung Ki JEONG ; Woo Cheon LEE ; Chun Gyun NA ; Yong Koo PARK
The Journal of the Korean Orthopaedic Association 1987;22(1):318-320
A case of intraneural ganglion, 5cm×2cm×1.5cm, which was located between the funiculi of the common peroneal nerve was excised completely under the operative microscope. There was no communication with adjacent bursa or joint.
Ganglion Cysts
;
Joints
;
Peroneal Nerve
3.Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea.
Ran hui CHA ; Shin Wook KANG ; Cheol Whee PARK ; Dae Ryong CHA ; Ki Young NA ; Sung Gyun KIM ; Sun Ae YOON ; Sejoong KIM ; Sang Youb HAN ; Jung Hwan PARK ; Jae Hyun CHANG ; Chun Soo LIM ; Yon Su KIM
Kidney Research and Clinical Practice 2017;36(1):68-78
BACKGROUND: We investigated the long-term effect of AST-120, which has been proposed as a therapeutic option against renal disease progression, in patients with advanced chronic kidney disease (CKD). METHODS: We performed post-hoc analysis with a per-protocol group of the K-STAR study (Kremezin study against renal disease progression in Korea) that randomized participants into an AST-120 and a control arm. Patients in the AST-120 arm were given 6 g of AST-120 in three divided doses, and those in both arms received standard conventional treatment. RESULTS: The two arms did not differ significantly in the occurrence of composite primary outcomes (log-rank P = 0.41). For AST-120 patients with higher compliance, there were fewer composite primary outcomes: intermediate tertile hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.38 to 1.01, P = 0.05; highest tertile HR 0.436, 95% CI 0.25 to 0.76, P = 0.003. The estimated glomerular filtration rate level was more stable in the AST-120 arm, especially in diabetic patients. At one year, the AST-120-induced decrease in the serum indoxyl sulfate concentration inversely correlated with the occurrence of composite primary outcomes: second tertile HR 1.59, 95% CI 0.82 to 3.07, P = 0.17; third tertile HR 2.11, 95% CI 1.07 to 4.17, P = 0.031. Furthermore, AST-120 showed a protective effect against the major cardiovascular adverse events (HR 0.51, 95% CI 0.26 to 0.99, P = 0.046). CONCLUSION: Long-term use of AST-120 has potential for renal protection, especially in diabetic patients, as well as cardiovascular benefits. Reduction of the serum indoxyl sulfate level may be used to identify patients who would benefit from AST-120 administration.
Arm
;
Compliance
;
Disease Progression*
;
Glomerular Filtration Rate
;
Humans
;
Indican
;
Korea*
;
Renal Insufficiency, Chronic
4.Erratum: Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea Volume 36, Issue 1, March 2017, Pages 68–.
Ran hui CHA ; Shin Wook KANG ; Cheol Whee PARK ; Dae Ryong CHA ; Ki Young NA ; Sung Gyun KIM ; Sun Ae YOON ; Sejoong KIM ; Sang Youb HAN ; Jung Hwan PARK ; Jae Hyun CHANG ; Chun Soo LIM ; Yon Su KIM
Kidney Research and Clinical Practice 2018;37(1):98-99
The values of y axis in Fig. 3 should be corrected. The authors would like to apologize for any inconvenience this has caused.
5.Optimal Stem Cell Transporting Conditions to Maintain Cell Viability and Characteristics.
Na Hee YU ; So Young CHUN ; Yun Sok HA ; Hyun Tae KIM ; Dae Hwan KIM ; Jeongshik KIM ; Jae Wook CHUNG ; Jun Nyung LEE ; Phil Hyun SONG ; Eun Sang YOO ; Bum Soo KIM ; Tae Gyun KWON
Tissue Engineering and Regenerative Medicine 2018;15(5):639-647
BACKGROUND: The preservation of stem cell viability and characteristics during cell transport from the bench to patients can significantly affect the success of cell therapy. Factors such as suspending medium, time, temperature, cell density, and container type could be considered for transport conditions. METHODS: To establish optimal conditions, human amniotic fluid stem cells' (AFSCs) viabilities were analyzed under different media {DMEM(H), DMEM/F-12, K-SFM, RPMI 1640, α-MEM, DMEM(L), PBS or saline}, temperature (4, 22 or 37 ℃), cell density (1 × 10⁷ cells were suspended in 0.1, 0.5, 1.0 or 2.0 mL of medium) and container type (plastic syringe or glass bottle). After establishing the transport conditions, stem cell characteristics of AFSCs were compared to freshly prepared cells. RESULTS: Cells transported in DMEM(H) showed relatively higher viability than other media. The optimized transport temperature was 4 ℃, and available transport time was within 12 h. A lower cell density was associated with a better survival rate, and a syringe was selected as a transport container because of its clinical convenience. In compare of stem cell characteristics, the transported cells with established conditions showed similar potency as the freshly prepared cells. CONCLUSION: Our findings can provide a foundation to optimization of conditions for stem cell transport.
Amniotic Fluid
;
Cell Count
;
Cell Survival*
;
Cell- and Tissue-Based Therapy
;
Female
;
Glass
;
Humans
;
Stem Cells*
;
Survival Rate
;
Syringes
6.Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease
Seon Ha BAEK ; Ran hui CHA ; Shin Wook KANG ; Cheol Whee PARK ; Dae Ryong CHA ; Sung Gyun KIM ; Sun Ae YOON ; Sejoong KIM ; Sang Youb HAN ; Jung Hwan PARK ; Jae Hyun CHANG ; Chun Soo LIM ; Yon Su KIM ; Ki Young NA
The Korean Journal of Internal Medicine 2019;34(4):858-866
BACKGROUND/AIMS:
Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT 00860431).
METHODS:
A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes.
RESULTS:
The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10-μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD.
CONCLUSIONS
Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.
7.In Vivo Safety and Regeneration of Long-Term Transported Amniotic Fluid Stem Cells for Renal Regeneration
Na hee YU ; So Young CHUN ; Yun Sok HA ; Hyun Tae KIM ; Eugene LIH ; Dae Hwan KIM ; Jeongshik KIM ; Jae Wook CHUNG ; Phil Hyun SONG ; Eun Sang YOO ; Sung Kwang CHUNG ; Dong Keun HAN ; Bum Soo KIM ; Tae Gyun KWON
Tissue Engineering and Regenerative Medicine 2019;16(1):81-92
BACKGROUND: Despite major progress in stem cell therapy, our knowledge of the characteristics and tissue regeneration potency of long-term transported cells is insufficient. In a previous in vitro study, we established the optimal cell transport conditions for amniotic fluid stem cells (AFSCs). In the present study, the target tissue regeneration of long-term transported cells was validated in vivo. METHODS: For renal regeneration, transported AFSCs were seeded on a poly(lactide-co-glycolide) scaffold and implanted in a partially resected kidney. The target tissue regeneration of the transported cells was compared with that of freshly harvested cells in terms of morphological reconstruction, histological microstructure reformation, immune cell infiltration, presence of induced cells, migration into remote organs, expression of inflammation/fibrosis/renal differentiation-related factors, and functional recovery. RESULTS: The kidney implanted with transported cells showed recovery of total kidney volume, regeneration of glomerular/renal tubules, low CD4/CD8 infiltration, and no occurrence of cancer during 40 weeks of observation. The AFSCs gradually disappeared and did not migrate into the liver, lung, or spleen. We observed low expression levels of proinflammatory cytokines and fibrotic factors; enhanced expression of the genes Wnt4, Pax2, Wt1, and Emx2; and significantly reduced blood urea nitrogen and creatinine values. There were no statistical differences between the performance of freshly harvested cells and that of the transported cells. CONCLUSION: This study demonstrates that long-term transported cells under optimized conditions can be used for cell therapy without adverse effects on stem cell characteristics, in vivo safety, and tissue regeneration potency.
Amniotic Fluid
;
Blood Urea Nitrogen
;
Cell- and Tissue-Based Therapy
;
Creatinine
;
Cytokines
;
Female
;
In Vitro Techniques
;
Kidney
;
Liver
;
Lung
;
Polyglactin 910
;
Regeneration
;
Spleen
;
Stem Cells
8.Quality of Life after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Prospective Multicenter Cohort Study.
Sang Gyun KIM ; Seon Mi JI ; Na Rae LEE ; Seung Hee PARK ; Ji Hye YOU ; Il Ju CHOI ; Wan Sik LEE ; Seun Ja PARK ; Jun Haeng LEE ; Sang Yong SEOL ; Ji Hyun KIM ; Chul Hyun LIM ; Joo Young CHO ; Gwang Ha KIM ; Hoon Jai CHUN ; Yong Chan LEE ; Hwoon Yong JUNG ; Jae J KIM
Gut and Liver 2017;11(1):87-92
BACKGROUND/AIMS: Endoscopic submucosal dissection (ESD) has been an established treatment for indicated early gastric cancer (EGC) without deterioration of quality of life (QOL) compared with surgical resection. The aim of this study was to evaluate long-term QOL in patients undergoing ESD for EGC. METHODS: Patients scheduled to undergo curative ESD for EGC were prospectively enrolled from 12 institutions between May 2010 and December 2011. Assessments of QOL with Korean versions of the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire-core (QLQ-C30) and a gastric cancer-specific questionnaire (STO22) were performed at baseline and at 7 days, 3 months, and 6 months after ESD. RESULTS: A total of 666 subjects were assessed for QLQ-C30 and QLQ-STO22. The mean QLQ-C30 score was 69.5 at baseline, 68.8 at 7 days, 73.1 at 3 months, and 73.2 at 6 months. The global health status on the EORTC QLQ-C30 was significantly improved after 3 and 6 months (p=0.0003 and p<0.0001, respectively). The QLQ-C30 and STO22 scores were not significantly different, or they only slightly deteriorated between before and immediately after ESD, but they were significantly improved after 3 and 6 months (p<0.05). CONCLUSIONS: QOL did not deteriorate immediately after ESD, and it improved more significantly at up to 6 months in patients who underwent curative ESD for EGC without significant complications.
Cohort Studies*
;
Global Health
;
Humans
;
Prospective Studies*
;
Quality of Life*
;
Stomach Neoplasms*
9.Short-Term Outcomes of Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer: A Prospective Multicenter Cohort Study.
Il Ju CHOI ; Na Rae LEE ; Sang Gyun KIM ; Wan Sik LEE ; Seun Ja PARK ; Jae J KIM ; Jun Haeng LEE ; Jin Won KWON ; Seung Hee PARK ; Ji Hye YOU ; Ji Hyun KIM ; Chul Hyun LIM ; Joo Young CHO ; Gwang Ha KIM ; Yong Chan LEE ; Hwoon Yong JUNG ; Ji Young KIM ; Hoon Jai CHUN ; Sang Yong SEOL
Gut and Liver 2016;10(5):739-748
BACKGROUND/AIMS: Endoscopic submucosal dissection (ESD) is an effective treatment for early gastric cancer (EGC) that has demonstrated a minimal risk of lymph node metastasis in retrospective studies. We sought to prospectively evaluate the short-term outcomes of ESD treatment in EGCs. METHODS: A prospective multicenter cohort study of neoplasms 3 cm or less in diameter at endoscopic size evaluation was performed in 12 Korean ESD study group-related university hospitals and the National Cancer Center. Resected specimens were evaluated by the central pathologic review board. RESULTS: A patient cohort (n=712) with a total of 737 EGCs was analyzed. The margin-freeen bloc resection rate was 97.3%, and curative resection of 640 lesions (86.8%) was achieved. Lower curative resection rates were associated with lesions 2 to 3 cm in size prior to ESD compared with lesions 2 cm or less in size (78.6% vs 88.1%, respectively, p=0.009). Significant factors associated with noncurative resection were moderately or poorly differentiated histological type, posterior wall tumor location, tumor size larger than 3 cm, ulceration, and submucosal invasion. Delayed bleeding occurred in 49 patients (6.9%), and 12 patients (1.7%) exhibited perforations. CONCLUSIONS: ESD is an effective treatment with a high curative resection rate for EGCs that meets relatively conservative pre-ESD indications. Long-term survival outcomes should be evaluated in follow-up studies.
Cohort Studies*
;
Endoscopy
;
Follow-Up Studies
;
Hemorrhage
;
Hospitals, University
;
Humans
;
Lymph Nodes
;
Neoplasm Metastasis
;
Prospective Studies*
;
Retrospective Studies
;
Stomach Neoplasms*
;
Ulcer
10.Long-Term Clinical Outcomes of Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer: A Prospective Multicenter Cohort Study.
Sang Gyun KIM ; Chan Mi PARK ; Na Rae LEE ; Jiyoung KIM ; Da Hyun LYU ; Seung Hee PARK ; Il Ju CHOI ; Wan Sik LEE ; Seun Ja PARK ; Jae Jun KIM ; Ji Hyun KIM ; Chul Hyun LIM ; Joo Young CHO ; Gwang Ha KIM ; Yong Chan LEE ; Hwoon Yong JUNG ; Jun Haeng LEE ; Hoon Jai CHUN ; Sang Yong SEOL
Gut and Liver 2018;12(4):402-410
BACKGROUND/AIMS: Endoscopic submucosal dissection (ESD) has been regarded as a curative treatment for early gastric cancer (EGC) in indicated cases. The aim of this study was to evaluate the nationwide long-term clinical outcomes of ESD for EGC in Korea. METHODS: A prospective multicenter cohort study was performed to evaluate the long-term efficacy of ESD for EGC within pre-defined indications at 12 institutes in Korea. The cases that met the expanded criteria upon pathological review after ESD were followed for 5 years. The primary outcome was 5-year disease specific free survival. RESULTS: Six hundred ninety-seven patients with 722 EGCs treated with ESD were prospectively enrolled and followed for 5 years. Complete resection was achieved in 81.3% of the cases, and curative resection was achieved in 86.1%. During the 5-year follow-up, the overall survival rate was 96.6%, and the disease specific free survival rate was 90.6%. Local recurrence developed in 0.9%, and metachronous tumor development occurred in 7.8%; both conditions were treated by endoscopic or surgical treatment. Distant metastasis developed in 0.5% during follow-up. CONCLUSIONS: ESD showed excellent long-term clinical outcomes and can be accepted as a curative treatment for patients with EGC who meet the expanded criteria in final pathology studies.
Academies and Institutes
;
Cohort Studies*
;
Follow-Up Studies
;
Humans
;
Korea
;
Neoplasm Metastasis
;
Pathology
;
Prospective Studies*
;
Recurrence
;
Stomach Neoplasms*
;
Survival Rate